This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Your ketoconazole may decrease the ability of your liver to remove the calcium channel blocker from your body.
What might happen:
The level of calcium channel blocker in your body may cause your blood pressure to decrease too much. Symptoms of low blood pressure include: irregular heartbeat, lightheadedness, nausea, drowsiness, confusion, and slurred speech. You may also notice swelling in your legs and/or feet.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to decrease the dose of your calcium channel blocker or may want to change your ketoconazole to another medicine. Let your doctor know right away if you develop any signs of low blood pressure, a decreased heart rate, or swelling of the legs.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/D rugInteractionsLabeling/ucm093664.htm. Updated 08/05/2011.
2.Nizoral (ketoconazole oral) US prescribing information. Janssen Pharmaceuticals February, 2014.
3.This information is based on or an extract from the UW Metabolism and Transport Drug Interaction Database (DIDB) Platform, Copyright University of Washington 1999-2014..
4.Heinig R, Adelmann HG, Ahr G. The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine. Eur J Clin Pharmacol 1999 Mar;55(1):57-60.
5.Liu XQ, Zhao Y, Li D, Qian ZY, Wang GJ. Metabolism and metabolic inhibition of cilnidipine in human liver microsomes. Acta Pharmacol Sin 2003 Mar;24(3):263-8.
6.Greenblatt DJ, Zhao Y, Venkatakrishnan K, Duan SX, Harmatz JS, Parent SJ, Court MH, von Moltke LL. Mechanism of cytochrome P450-3A inhibition by ketoconazole. J Pharm Pharmacol 2011 Feb;63(2):214-21.